Primary Care Diabetes
Volume 3, Issue 1 , Pages 57-59 , February 2009

The new rosiglitazone story: Its place today in Type 2 diabetes management

Received 20 October 2008 ,Accepted 31 January 2009.

References 

  1. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 2008;359(15):1577–1589
  2. Oral presentations, Duckworth W, ADA 2008, EASD 2008.
  3. Effects of Intensive Glucose Lowering in Type 2 Diabetes—The Action to Control Cardiovascular Risk in Diabetes Study Group, NEJM 12th June 2008, Vol. 358, pp. 2545–2559.
  4. Kahn S, et al. for the ADOPT study group Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 2006;355:2427–2443
  5. Avandia SPC, accessed 19 October 2008, http://emc.medicines.org.uk/emc/assets/c/html/DisplayDoc.asp?DocumentID=3200.
  6. DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) Trial Investigators . Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368:1096–1105
  7. Rosiglitazone Evaluated for Cardiac Outcomes, an Interim Analysis NEJM July 7th 2007, Vol. 357, pp. 28–38.
  8. http://www.fda.gov/ohrms/dockets/ac/cder07.htm#EndocrinologicMetabolic
  9. Margolis D, Hoffstad O, Strom B. Association between serious ischaemic cardiac outcomes and medications used to treat diabetes. Pharmacoepidemiol. Drug Safe. 2008;17:753–759

PII: S1751-9918(09)00005-9

doi: 10.1016/j.pcd.2009.01.002

Primary Care Diabetes
Volume 3, Issue 1 , Pages 57-59 , February 2009

Article Tools